TABLE 1.
Clinical and laboratorial parameters at inclusion.
| Parameter | All patients | Severe | Critical | P-value |
| Female/male | 14/16 | 4/7 | 5/7 | |
| Age (y) | 51.6 ± 11.5 | 55.7 ± 3.1 | 49 ± 3.2 | 0.07 |
| BMI (kg/m2) | 30.6 ± 6.7 | 29 ± 2.0 | 31.8 ± 2.3 | 0.36 |
| Symptoms onset (d) | 8.1 ± 2.5 | 8.1 ± 0.6 | 8.2 ± 0.7 | 0.75 |
| SatO2 (%) | 91.4 ± 4.7 | 94.8 ± 1.0 | 95.6 ± 2.9 | 0.58 |
| Lung CT score | 17.8 ± 7.3 | 13.2 ± 1.6 | 22.7 ± 1.6 | <0.01 |
| Systolic blood pressure (mm Hg) | 124 ± 18 | 134.4 ± 5.6 | 121 ± 2.7 | 0.08 |
| <90 mm Hg (n) | 1 (3.3%) | 0 (0%) | 1 (8.3%) | |
| Diastolic blood pressure (mm Hg) | 76.7 ± 12.7 | 86.9 ± 2.7 | 72.0 ± 3.0 | <0.01 |
| <60 mm Hg (n) | 0 (0%) | 0 (0%) | 0 (0%) | |
| White cell count (×109/L) | 7.76 ± 4.0 | 7.0 ± 1.3 | 8.4 ± 0.9 | 0.24 |
| <4 × 109/L (n) | 5 (16.7%) | 3 (27.3%) | 1 (8.3%) | |
| 4–10 × 109/L (n) | 20 (66.7%) | 7 (63.6%) | 8 (66.7%) | |
| >10 × 109/L (n) | 5 (16.7%) | 1 (9%) | 3 (25%) | |
| Lymphocyte count (×109/L) | 1.18 ± 0.48 | 1.13 ± 0.2 | 1.15 ± 0.1 | 0.41 |
| <1 × 109/l (n) | 9 (33.3%) | 4 (44.4%) | 4 (36.4%) | |
| >1 × 109/l (n) | 18 (66.7%) | 5 (55.6%) | 7 (63.6%) | |
| Platelet count (×109/L) | 221.7 ± 93.4 | 214.2 ± 38.9 | 199.3 ± 16.5 | 0.79 |
| <100 × 109/L (n) | 1 (3.3%) | 1 (9.1%) | 0 (0%) | |
| ≥100 × 109/L (n) | 29 (96.7%) | 10 (90.9%) | 12 (100%) | |
| Plasma glucose (mg/dL) | 172.7 ± 96.2 | 125.6 ± 16.4 | 145.1 ± 10.6 | 0.06 |
| <125 (mg/dL; n) | 13 (43.3%) | 8 (72.7%) | 5 (41.7%) | |
| >125 (mg/dL; n) | 17 (56.7%) | 3 (27.3%) | 7 (58.3%) | |
| Serum creatinine (mg/dL) | 1.00 ± 0.61 | 0.87 ± 0.07 | 1.23 ± 0.26 | 0.34 |
| <1.2 (mg/dL; n) | 26 (86.7%) | 10 (90.9%) | 9 (75%) | |
| >1.2 (mg/dL; n) | 4 (13.3%) | 1 (9.1%) | 3 (25%) | |
| AST (U/L) | 61.8 ± 62.2 | 74.7 ± 29.3 | 55.17 ± 5.5 | 0.53 |
| <40 (U/L; n) | 11 (37.9%) | 5 (50%) | 2 (16.7%) | |
| >40(U/L; n) | 18 (62.1%) | 5 (50%) | 10 (83.3%) | |
| ALT (U/L) | 48.3 ± 52.7 | 66.4 ± 25.6 | 38.3 ± 4.9 | 0.63 |
| <40 (U/L; n) | 17 (58.6%) | 6 (60%) | 6 (50%) | |
| ≥40(U/L; n) | 12 (41.4%) | 4 (40%) | 6 (50%) | |
| LDH (U/L) | 362.2 ± 176.0 | 287.2 ± 21.3 | 477.6 ± 70.2 | <0.01 |
| <245 (U/L; n) | 5 (17.9%) | 4 (36.4%) | 1 (9.1%) | |
| ≥245 (U/L; n) | 23 (82.1%) | 7 (63.6%) | 10 (90.9%) | |
| C-Reactive Protein (mg/L) | 117.6 ± 74.3 | 74.7 ± 11.6 | 154.1 ± 24.5 | <0.05 |
| <10 (mg/L; n) | 0 (0%) | 0 (0%) | 0 (0%) | |
| ≥10 (mg/L; n) | 29 (100%) | 11 (100%) | 12 (100%) |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CK, creatine kinase; and LDH, lactate dehydrogenase. Unpaired Student t-test was used to compare Severe × Critical conditions.